Location
Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, Colorado
Hotel Phone: (303) 436-1234
Program Schedule — Mountain Time
5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting
Meeting Room
Capitol Ballroom (Fourth Floor)
Faculty Jacqueline Broadway-Duren, PhD, DNP, APRN, FNP-BC
Family Nurse Practitioner
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Bita Fakhri, MD, MPH
Assistant Professor of Medicine (Hematology)
Stanford University School of Medicine
Stanford, California
Corinne Hoffman, MS, APRN-CNP, AOCNP
Nurse Practitioner, Hematology
The James Comprehensive Cancer Center
The Ohio State University Wexner Medical Center
Columbus, Ohio
Jeff Sharman, MD
Medical Director of Hematology Research
Sarah Cannon Research Institute at
Willamette Valley Cancer Center
Eugene, Oregon
Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP and Lilly during the Oncology Nursing Society’s (ONS) 50th Annual Congress, April 9-13, 2025 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Mountain Time
5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting
Current Approaches to First-Line Treatment for Chronic Lymphocytic Leukemia (CLL)
Indications for initiating active therapy for previously untreated CLL
Implications of various biomarkers (eg, IGHV mutation, del[17p], TP53 mutation) for prognosis and therapeutic selection
Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for treatment-naïve and relapsed/refractory (R/R) CLL; application in current up-front decision-making
Comparative antitumor activity of Bruton tyrosine kinase (BTK) inhibitors alone or in combination with anti-CD20 antibodies in the up-front setting; implications for therapeutic selection
Outcomes observed with venetoclax-based up-front treatment for CLL
Potential Role of Therapy Combining BTK Inhibitors and Venetoclax
Mechanistic rationale for combining BTK inhibitors and venetoclax with or without CD20 antibodies for CLL
Published datasets evaluating ibrutinib/venetoclax for newly diagnosed and R/R CLL
Recently presented positive findings with fixed-duration acalabrutinib in combination with venetoclax with or without obinutuzumab for previously untreated CLL
Potential role of novel doublet and triplet combinations for previously untreated CLL
Impact of Comorbid Conditions and Other Practical Considerations on the Choice of First-Line Therapy for Newly Diagnosed CLL
Comorbidities (eg, hypertension, preexisting cardiac arrhythmias, chronic kidney disease) that may influence clinical decision-making for patients with CLL
Impact of concomitant medications (eg, anticoagulants) on the choice of CLL therapy
Potential interactions between BTK inhibitors or venetoclax and other prescription drugs/over-the-counter medications and supplements
Educating patients on the potential benefits and disadvantages of time-limited and continuous up-front therapy
Tolerability of BTK Inhibitors
Incidence and severity of cardiac arrhythmias, including atrial fibrillation/flutter, documented with approved BTK inhibitors
Probability of other cardiovascular toxicities (eg, stroke, hypertension, bruising/bleeding events) with BTK inhibitor therapy
Spectrum and frequency of clinically relevant noncardiovascular toxicities, including cytopenias, infections, headache, dermatologic issues, arthralgias/myalgia and gastrointestinal events, with BTK inhibitors
Appropriate monitoring for and management of treatment-related cardiovascular and noncardiovascular events in patients receiving BTK inhibitors
Toxicities Associated with Venetoclax-Based Treatment
Key factors placing patients at risk for tumor lysis syndrome (TLS) with venetoclax
Approaches to monitoring for and management of laboratory and clinical TLS
Spectrum, incidence, severity and management of other toxicities reported with venetoclax (eg, neutropenia, infections, gastrointestinal disorders)
Incidence and severity of clinically relevant toxicities encountered when combining venetoclax and BTK inhibitors with or without anti-CD20 antibodies
Role of Noncovalent BTK Inhibitors in R/R CLL
Pharmacologic similarities and differences between covalent and noncovalent BTK inhibitors
Antitumor activity documented with pirtobrutinib for R/R CLL, including among patients who have experienced disease progression on covalent BTK inhibitors
Tolerability of pirtobrutinib relative to available covalent BTK inhibitors
FDA approval and current clinical role of pirtobrutinib for R/R CLL
Other Available Therapies for R/R CLL
Published efficacy and safety findings with lisocabtagene maraleucel (liso-cel) for R/R CLL
FDA approval of liso-cel for CLL previously treated with a BTK inhibitor and a Bcl-2 inhibitor; optimal patient selection
Antitumor activity observed with novel treatment strategies in patients with CLL and Richter’s transformation
Other promising agents and strategies under investigation for CLL
Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia (CLL).
Learning Objectives
Upon completion of this activity, participants should be able to
Individualize the selection of systemic therapy for newly diagnosed CLL, considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
Evaluate available Phase III data demonstrating the efficacy and safety of Bruton tyrosine kinase (BTK) inhibition as first-line therapy for CLL, and use this information to counsel patients regarding available front-line options.
Understand published research findings with Bcl-2 inhibitors in combination with anti-CD20 antibodies as first-line treatment for CLL, and counsel patients regarding the risks and benefits of this novel therapeutic strategy.
Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy for patients with newly diagnosed CLL.
Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory CLL to provide education regarding appropriate treatment considerations.
Discuss available clinical research findings demonstrating the efficacy and safety of noncovalent BTK inhibitors for patients with CLL, and identify candidates for whom treatment with these agents would be appropriate.
Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for CLL.
Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2025/CLL/ILNA
Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.
Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Ms Hoffman has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Dr Broadway-Duren — Advisory Committees: AbbVie Inc, BeiGene Ltd.
Dr Fakhri — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, BeiGene Ltd, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Speakers Bureaus: AbbVie Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company.
Dr Sharman — Consulting Agreements and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Lilly, Merck.
RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Lilly.
Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room
Capitol Ballroom (Fourth Floor)
The Hyatt Regency Denver at Colorado Convention Center is the headquarters hotel for the 2025 ONS Congress and is adjacent to the Colorado Convention Center.
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia.
There is no registration fee for this event. For the in-person symposium in Denver, preregistration is required as seating is limited.
NOTICE: Registration for this event is independent of registration for the 2025 ONS Congress.
IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
